{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:25:11Z","timestamp":1775913911374,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02711-x","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T07:02:21Z","timestamp":1701846141000},"page":"618-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension"],"prefix":"10.1007","volume":"41","author":[{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Rahaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Elwing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Pepke-Zaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelon","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yuanhua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cadaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliou","family":"Ousmanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-5206","authenticated-orcid":false,"given":"R. James","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the FREEDOM-EV Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"2711_CR1","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;61:2200879.","journal-title":"Eur Respir J"},{"issue":"21","key":"2711_CR2","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2711_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","volume":"30","author":"RL Benza","year":"2011","unstructured":"Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30(12):1327\u201333.","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"2711_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","volume":"60","author":"RJ Oudiz","year":"2012","unstructured":"Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768\u201374.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2711_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","volume":"201","author":"RJ White","year":"2020","unstructured":"White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2711_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"2711_CR7","doi-asserted-by":"publisher","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","volume":"50","author":"A Boucly","year":"2017","unstructured":"Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889\u201399.","journal-title":"Eur Respir J"},{"issue":"3","key":"2711_CR8","doi-asserted-by":"publisher","first-page":"1702606","DOI":"10.1183\/13993003.02606-2017","volume":"51","author":"MM Hoeper","year":"2018","unstructured":"Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3):1702606.","journal-title":"Eur Respir J"},{"key":"2711_CR9","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Pausch C, Olsson KM, et al. COMPERA\u00a02.0: a refined four-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1):2102311.","DOI":"10.1183\/13993003.02311-2021"},{"issue":"1","key":"2711_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","volume":"159","author":"RL Benza","year":"2021","unstructured":"Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite\u00a02, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337\u201346.","journal-title":"Chest"},{"issue":"11","key":"2711_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.healun.2022.08.006","volume":"41","author":"RL Benza","year":"2022","unstructured":"Benza RL, Gomberg-Maitland M, Farber HW, et al. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension\u2014an analysis of FREEDOM-EV. J Heart Lung Transplant. 2022;41(11):1572\u201380.","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"2711_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S2213-2600(16)30307-1","volume":"4","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016;4(11):894\u2013901.","journal-title":"Lancet Respir Med"},{"issue":"26","key":"2711_CR13","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"2711_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.healun.2017.11.006","volume":"37","author":"RL Benza","year":"2018","unstructured":"Benza RL, Farber HW, Frost A, et al. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2018;37(4):513\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"2711_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.healun.2014.09.016","volume":"34","author":"RL Benza","year":"2015","unstructured":"Benza RL, Miller DP, Foreman AJ, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2015;34(3):356\u201361.","journal-title":"J Heart Lung Transplant"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02711-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T05:15:50Z","timestamp":1707023750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02711-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02711-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors have declarations of support from organizations for the submitted work: Ekkehard Gr\u00fcnig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, Antoine Hage, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, Yang Yuanhua, Zaixin Yu, James Lordan, Linda Cadaret and R. James White received institutional funding from United Therapeutics in order to conduct the study at their respective institutions. Ekkehard Gr\u00fcnig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, and Linda Cadaret have received support for consultation, advisory and\/or speaker bureau from United Therapeutics. Rob Grover, Aliou Ousmanou, Scott Seaman, Chunqin Deng, and Meredith Broderick are employees of United Therapeutics. Below, is a summary of each authors\u2019 disclosures, related and unrelated to the submitted work. Ekkehard Gr\u00fcnig\u2014Received fees for lectures and\/or consultations from Actelion, Bayer\/MSD, Ferrer, GEBRO, GSK, Janssen and OMT. Research grants to his institution have been received from Acceleron, Actelion, BayerHealthCare, MSD, Bellerophon, GossamerBio, GSK, Janssen, Novartis, OMT, Pfizer, REATE and United Therapeutics. Franck Rahaghi\u2014received research support, serving on Advisory Board, Consultation and\/or Speaker bureau for United Therapeutics; grants or contracts from Bayer, Janssen PH, and Acceleron. Jean Elwing\u2014received grant\/research support and\/or serving on Advisory Boards for Janssen, United Therapeutics, Liquidia, Phase Bio, Gossamer Bio, Bayer, Acceleron\/Merck, Altavant, Aerovate, Tenax, and Pharmosa. Carmine Dario Vizza\u2014received grant\/research support and\/or serving on Advisory Boards or as a consultant for Ferrier, GSK, MSD, Bayer Actelion and United Therapeutics. Joanna Pepke-Zaba\u2014received honoraria for lecturing and consulting from Bayer, Actelion, and GSK; on advisory boards for Actelion, Pfizer, Bayer, GSK, and United Therapeutics. Jieyan Shen\u2014received institutional funding from United Therapeutics in order to conduct the study at their institution. Hua Yao\u2014received institutional funding from United Therapeutics in order to conduct the study at their institution. Antoine Hage\u2014received research grant\/support from Actelion, Bayer, United Therapeutics, REATA and Arena. Stephan Rosenkranz\u2014received research grants or contracts from Actelion, AstraZeneca, Bayer, Janssen, and Novartis; consulting fees from Abbott, Acceleron, Actelion, Bayer, Janssen, MSD, Novartis, Pfizer, United Therapeutics, and Vifor; and payment or honoraria from Actelion, Bayer, BMS, Ferrer, GSK, Janssen, MSD, Novartis, Pfizer, United Therapeutics, and Vifor. Madelon Vonk\u2014Received research support, serving on Advisory Board, Consultation and\/or Speaker bureau for Actelion, Boehringer Ingelheim, Ferrier, GSK, and Roche. Vijay Balasubramanian\u2014received research support, serving on Advisory Board, Consultation and\/or Speaker bureau for United Therapeutics, Bayer, and Boehringer Ingelheim. Yuanhua Yang\u2014received institutional funding from United Therapeutics in order to conduct the study at their institution. Zaixin Yu\u2014Received institutional funding from United Therapeutics in order to conduct the study at their institution. James Lordan\u2014received institutional funding from United Therapeutics in order to conduct the study at their institution. Linda Cadaret\u2014received grant\/ research support and\/or serving on Advisory Boards for United Therapeutics. Rob Grover\u2014employee of the United Therapeutics\u2014sponsor of the study. Aliou Ousmanou\u2014employee of the United Therapeutics\u2014sponsor of the study. Scott Seaman\u2014employee of the United Therapeutics\u2014sponsor of the study. Chunqin Deng\u2014employee of the United Therapeutics\u2014sponsor of the study. Meredith Broderick\u2014employee of the United Therapeutics\u2014sponsor of the study. R. James White\u2014received research support (payment to institution only) from United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol and all study-related documents were approved by the institutional review board or independent ethics committee for each site. The full list of institutional review board and independent ethic committee names, locations, and serial numbers can be found in the Supplementary Materials. The study was conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}